Therefore, we sought to elucidate the aforementioned relationships by conducting a prospective study to analyze the leptin levels adjusting for viral, metabolic, and immune profiles in genotype 1 (G1) and genotype 2 (G2) CHC patients who completed anti-HCV therapy. This evidence concerns the gene LEP and cryohydrocytosis.